Table 3.
Clinicopathological characteristics of PIK3CA amplification in TAs and SSAs
| TA (n = 64) | p | SSA (n = 32) | p | |
|---|---|---|---|---|
| Total * | 25.0% (16/64) | 9.4% (3/32) | ||
| Sex | 0.28 | 0.22 | ||
| Male | 20.9% (9/43) | 13.6% (3/22) | ||
| Female | 33.3% (7/21) | 0% (0/10) | ||
| Side | 0.025 | 0.34 | ||
| Right | 5.6% (1/18) | 0% (0/7) | ||
| Left | 32.6% (15/46) | 12.0% (3/25) | ||
| MSI | 1.00 | 1.00 | ||
| (+) | 28.6% (2/7) | 0% (0/4) | ||
| (-) | 24.6% (14/57) | 10.7% (3/28) | ||
| KRAS mutation | 0.06 | 0.74 | ||
| (+) | 6.7% (1/15) | 0% (0/1) | ||
| (-) | 30.6% (15/49) | 9.7% (3/31) | ||
| BRAF mutation | - | 0.50 | ||
| (+) | - | 16.7% (1/6) | ||
| (-) | 25.0% (16/64) | 7.7% (2/26) |
*p = 0.07 between TA and SSA